To Medicate or Not

Preview:

DESCRIPTION

Parent Education Parent Coaching Parent Learning Center Back to Topics To Medicate or Not [presentation] The following presentation by Children’s Health Council Chief Psychiatrist and Medical Director Glen Elliott, Ph.D, M.D., explores treatment options for ADHD.

Citation preview

Children’s Health Council

1

Glen R. Elliott, PhD, MD Chief Psychiatrist & Medical Director

To Medicate or Not

Children’s Health Council

Our Vision

At Children’s Health Council, we believe there is a world of promise and potential in every child.

Using a personalized approach, we help children become happier, more resilient and more successful.

Children’s Health Council

Our Mission

Our mission is to help children with ADHD, LD, Anxiety & Depression and ASD thrive by promoting Social Emotional Learning, Academics, Executive Functioning and Physical Development.

Children’s Health Council

4

Our Framework for Learning & Life Success

Happy, resilient and

thriving children

Social Emotional Learning

Academic Success

Executive Functioning

Physical Development

Children’s Health Council

The Center at CHC

Sand Hill School

Esther B. Clark School

Community Clinic at CHC

Integrated Learning

Expert interdisciplinary assessments, tr

eatments & programs

Personalized learning for students in K-5, expanding to K-8

Transformative help for

emotionally challenged

children ages 7-16

Nurturing care for families served by Medi-Cal

5

Empowering Success through Four Divisions

Children’s Health Council

6

On the Agenda

• Broad observations about ADHD and treatment

• A model for working with a prescribing doctor

• Current approaches to treating ADHD with medications

• Some common patterns and problems parents encounter

• Q&A

Children’s Health Council

7

• Non-medication treatment approaches (9.25.13)

• Children with lots of sensory issues (10.2.13)

• Highly complicated situations where ADHD is only a small part of the problem

• Solving specific problems about specific children

NOT On the Agenda

Children’s Health Council

For many with ADHD, the disorder is

chronic and potentially life-long

Children’s Health Council

Broad Observations about ADHD

Children’s Health Council

10

• On average, over time, symptoms become less severe

• A variety of interventions clearly can reduce symptoms, at least in the short run

• Some features of ADHD can be real strengths in the right setting and context

Good News

Children’s Health Council

11

• No existing treatments seem to change the long-term course of ADHD

• Inadequately treated ADHD makes other developmental goals much harder to attain

• When ADHD occurs with another problem (about 2/3 of the time), outcomes tend to be worse

• All treatments have the potential for side effects

Bad News

Children’s Health Council

12

• ADHD is a chronic disorder

• Impairment takes many forms

• Issues change with time

• Both medication and non-medication strategies can be effective—and both may be needed

General Points on Treating ADHD

Children’s Health Council

13

Environmental

• Structural

• Programmatic

Psychological

• Cognitive/Behavioral

• Intrapsychic

Possible Points of Intervention

Biological

• Medications

• Nutritional changes

Children’s Health Council

A Model for Using Medications to Treat

ADHD

Children’s Health Council

15

• Meet regularly, especially early in treatment

• Talk about:

– Likely side effects

– Agreed-upon useful positive targets

– How best dose will be determined

– Monitoring

Working with Your Doctor

Children’s Health Council

16

• Pick a medication

– 65% of ADHD subjects will do well on first stimulant

– 15%-20% will respond well to a second stimulant

• Choose between short- or long-acting

– Short-acting forms out of favor but allow tailoring of dose

– Long-acting forms have differing durations and release patterns

Selecting Medication

Children’s Health Council

17

Determine who should have input on benefits and adverse effects:

• Parent(s)

• Child

• Teacher(s)

• Others?

It Takes A Village

Children’s Health Council

18

• Establish communication between key caregivers, for example, teacher(s)

– Make a tailored, brief checklist of key symptoms and behaviors

– Ask teacher regularly to indicate how child is doing and share feedback, preferably in chart form, at each visit

It Takes A Village (cont.)

Children’s Health Council

19

• Keep records!

– Medication form and dose

– Height and weight

– Any other changes you think might be relevant

• Communicate!

– Concerns over possible side effects

– Fading benefits

– Any other worries that interfere with treatment

Best Practices

Children’s Health Council

20

• Do not make changes at key transitions, e.g., just as school is starting or in the middle of finals

– Older, bigger children may need greater daily dosages and different types of coverage for optimal benefit

– NB: puberty is apt to change symptom presentation and possibly dosage needs (higher or lower)

Best Practices (cont.)

Children’s Health Council

Medication Options

Children’s Health Council

22

• Extensive evidence supports the conclusion that specific medications can improve the core symptoms of ADHD: inattention, distractibility, impulsivity and hyperactivity

• Available medications have little to no direct effect on executive functioning and social skills

• For better or worse, medication-induced changes are not permanent

• Research has yet to suggest that medications (or any other intervention) change the underlying course of ADHD

General Observations

Children’s Health Council

23

• Stimulants

– methylphenidate

– amphetamine

• Non-Stimulants

– atomoxetine (Strattera)

– guanfacine (Tenex, Intuniv)

– clonidine (Kapvay, Catapres patch)

• Others less well-established or less used

Medication Options

Children’s Health Council

24

• Highly effective

• Act very quickly

• Can be used selectively—given only when needed

• A variety of different forms are available to tailor the action during the day

Stimulants: Advantages

Children’s Health Council

25

• Only cover part of the day

• Not especially useful early and late in the day

• Prescribing is restricted

• Have well-known side effects:

– Depressed appetite with weight loss

– Possible effect on decreased height

– Insomnia

– Uncover or worsen tics

Stimulants: Disadvantages

Children’s Health Council

26

Methylphenidate

Brand Name Type Dose Forms (mg)Estimated Duration

Generic IR* 5, 10, 20 2.5-3 hrs

Concerta ER** 18, 27, 36, 54 10-12 hrs

Focalin(dexmethylphenidate)

IR*

XR**

2.5, 5, 10

5, 10, 15, 20

3-4 hrs

8-12 hrs

MetadzateCD**ER*

10, 20, 30, 40, 50, 60

10, 20

8-10 hrs

6-8 hrs

*tablet **capsule

Children’s Health Council

27

Methylphenidate (cont.)

Brand Name Type Dose Forms (mg)Estimated Duration

Methylin

IR*

Chewtabs

SolutionER

5, 10, 20

2.5, 5, 10

5/5ml; 10/5ml10, 20

2.5-3 hrs

2.5-3 hrs

2.5-3 hrs6-8 hrs

RitalinIR*LA**

5, 10, 2010, 20, 30, 40

2.5-3 hrs 8-10 hrs

*tablet **capsule

Children’s Health Council

28

Methylphenidate (cont.)

Brand Name Type Dose Forms (mg)Estimated Duration

Datrana Patch 10, 20, 30 10+ hrs

Methylin

IR*

Chewtabs

IR†

ER

5, 10, 20

2.5, 5, 10

5/5ml; 10/5ml10, 20

2.5-3 hrs

2.5-3 hrs

2.5-3 hrs6-8 hrs

Quillivant XR ER† 10, 20, 30, 40, 50, 60 mg 10-12 hrs

*tablet **capsule †solution or suspension

Children’s Health Council

29

Brand Name Form Release pattern Duration

ConcertaInsoluble capsule

28% IR, then ascending curve

10-12 hrs

Ritalin LA

Focalin XR

Capsule with beads

50% IR, 50% at 4 hours

6-8 hrs

8-10 hrs

Metadate CDCapsule with

beads30% IR, 70% at 4

hours6-8 hrs

Metadate ER Wax matrix Steady release 8-10 hrs

Differences in Long-Acting Forms of Methylphenidate

Children’s Health Council

30

Other Stimulants

Name/ Brand Type Dose Forms (mg)EstimatedDuration

amphetamineDextrostat IR** 5, 10 4-6 hrs

DexedrineDexedrine Spansule

IR*ER**

55, 10, 15

4-6 hrs10-12 hrs

AdderallAdderall XR

IR*XR**

5, 7.5, 10, 12.5, 15, 20, 3010, 20, 30

4-6 hrs10-12 hrs

ProCentra IR† 5 mg/5ml 3-4 hrs

lisdexamfetamine

Vyvanse

Pro-drug**

20, 30, 40, 50, 60, 70 12-24 hrs

*pills **capsules †solution

Children’s Health Council

31

• Can provide 24-hour coverage

• When effective, have benefits quite comparable to those of stimulants

• Tend to have side effects quite different from stimulants (e.g., sedating, less effect on appetite)

• Easier to prescribe

Non-Stimulants: Advantages

Children’s Health Council

32

• Often take weeks to work

• Do not work for as many individuals (40% vs. 65%)

• Side effects may be unacceptable, especially daytime tiredness and sedation

• Seem less likely to provide “cognitive boost”

Non-Stimulants: Disadvantages

Children’s Health Council

33

• Nonstimulant

• Mechanism of action thought to be selective noradrenergic reuptake inhibition

• Available as 10, 18, 25, 40 & 60 mg capsules

• Dosing is once or twice daily, continuous

• Recommended dose formally up to 1.2 mg/kg/d; some suggesting up to 1.8

Atomoxetine (Strattera)

Children’s Health Council

34

• Some delay in action, with continued accrual of benefits over weeks to months

• Common side effects: nausea (sometimes vomiting) and daytime sedation

• Has black-box warning for suicidal ideation; theoretical risk of inducing mania

• Estimated efficacy is 40-45% of patients

• Compatible with concurrent use of stimulants

Atomoxetine (cont.)

Children’s Health Council

35

• Nonstimulant

• Mechanism of action thought to be pre-synaptic noradrenergic receptor activation

• Available as 1 or 2 mg tablets for guanfacine (Tenex) or as 1, 2, 3 or 4 mg tablets for Intuniv

• Dosing is continuous, 1-2 times daily, for guanfacineor once daily usually in AM for Intuniv

• Usual dose range is 2 to 4 mg per day

• NB: Only Intuniv has FDA endorsement for ADHD

Guanfacine (Tenex, Intuniv)

Children’s Health Council

36

• Some delay in action, with continued accrual of benefits over weeks to months

• Estimated efficacy is 40-45% of patients

• Common side effects are daytime sedation but sometimes disrupts sleep; may lower blood pressure

• NOT thought to carry risk of inducing mania

Guanfacine (cont.)

Children’s Health Council

37

• Nonstimulant

• Mechanism of action thought to be pre-synaptic noradrenergic receptor activation

• Available as 0.1 mg tablets for Kapvay or as TTS 0.1, 0.2 and 0.3 mg patches that last 5-7 days

• Dosing is continuous, 2x daily for Kapvay, once every 4-7 days for patch

• Usual dose range is 0.2 to 0.4 mg per day

• NB: Only Kapvay has FDA endorsement for ADHD

Clonidine (Kapvay, Catapres patch)

Children’s Health Council

38

• Some delay in action, with continued accrual of benefits over weeks to months

• Absorption of Intuniv is only about 60%

• Estimated efficacy is 40-45% of patients

• Common side effects are daytime sedation but sometimes disrupts sleep; may lower blood pressure

• Abrupt discontinuation can lead to potentially dangerous sudden spike in blood pressure

• NOT thought to carry risk of inducing mania

Clonidine (cont.)

Children’s Health Council

39

Other Non-Stimulant Antidepressants

Generic (Brand) Dose Forms (mg)Doses/

DayMaximum Daily Dose

bupropion

(Wellbutrin)

(Wellbutrin SR)

(Wellbutrin XL)

75, 100100, 150

150, 300

2

2

1

450 mg/d

imipramine (Tofranil) 10, 25, 50 2 3.5 mg/kg/d

nortriptyline (Pamelor) 10, 25, 50, 75 2 3 mg/kg/d

venlafaxine (Effexor)

(Effexor XR)

37.5. 75

37.5, 75, 150

2

1

225-300 mg/d

modafinil (Provigil) 100, 200 1 ? 500 mg

Children’s Health Council

40

• No major breakthroughs readily obvious

• Improved executive functioning is a highly desirable target, but no evidence to date of a medication that is directly helpful

• Some focus on other brain systems—nicotinic, NMDA—but data equivocal

What’s in the Offing?

Children’s Health Council

Common Patterns

Children’s Health Council

42

• Early morning issues

– Cannot complete morning routines

– May need 24-hour coverage

• School day issues

– Nearly universal

– Excellent coverage with most medications

• After-school issues

– Increase with older children/adolescents

– May need supplemental treatment

Diurnal Stress Points

Children’s Health Council

43

• Evening and bedtime issues

– May or may not be medication related

– Stimulants rarely helpful

– May need to consider non-stimulant alternatives or additions

Diurnal Stress Points (cont.)

Children’s Health Council

44

• Anxiety

– May get better with ADHD treatment

– If not, consider either broader coverage (atomoxetine or guanfacine) or addition of second medication (antidepressant)

• Tic Disorders

– Try medicine that works for both (alpha agonist)

– Try medicine neutral to tics (antidepressant)

– Use stimulant and tic-suppressing medication

Comorbid Conditions

Children’s Health Council

45

• Oppositional Defiant Disorder

– May respond to effective ADHD treatment

– No strong studies show good medication response specific to ODD

• Sleep Problems

– Some (15%) may sleep better with stimulants

– Non-stimulant medications usually sedating

Comorbid Conditions (cont.)

Children’s Health Council

46

• ADHD is a disorder that is chronic but responsive to treatment

• Optimal treatment requires ongoing, regular contact with client, family and school

• Complicated cases demand persistent reassessment and systematic approaches

Conclusion

Children’s Health Council

Questions?

Children’s Health Council

48

• Maybe you know my kid: A parents guide to identifying, understanding, and helping your child with ADHD (2nd ed.).

• Maybe you know my teen: A parents guide to adolescents with ADHD. Fowler, Mary Cahill (2001).

• Medicating Young Minds: How to Know if Psychiatric Drugs will Help or Hurt Your Child. Elliott, G. R., and Kelley, K. (2006)

• Taking Charge of ADHD: The complete authoritative guide for parents. Barkley, R. A. (2005).

• The CHADD Information and Resource Guide to AD/HD. CHADD (2001).

• Straight Talk About Psychiatric Medications for Kids. Wilens, T. E. (2008)

Resources: Books

Children’s Health Council

49

• CHADD Organization: chadd.org

• ADD Organization: add.org

• Charles Schwab Foundation (for LD): SchwabLearning.org

• Council for Exceptional Education (CEC): cec.sped.org

• American Academy of Child & Adolescent Psychiatry: aacap.org

• American Academy of Pediatrics: aap.org

• Learning Disabilities Association of America (LDA): ldanatl.org

• National Institute of Mental Health: help4adhd.org

• National Information Center for Children and Youth with Disabilities: nichcy.org

• ADD Warehouse: addwarehouse.com

• GSI Publications: gsi.com

• Guilford Publications: guilford.com

• Dr. Barkley: russellbarkley.org

Resources: Websites

Children’s Health Council

50

650.688.3625

care@chconline.org

Thank You for Coming

Recommended